Novo-Nordisk A/S Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 2/14/2026)
| Balance Sheet | Total Assets | 542,902,000,000.00 | ROE | 35.74 % |
| Balance Sheet | Total Equity | 194,047,000,000.00 | ROA | 18.87 % |
| Cashflow | Capital Expenditures | -90,113,000,000.00 | P/FCF | 19.31 |
| Cashflow | Free Cash Flow | 58,962,001,920.00 | – | – |
| Cashflow | Operating Cash Flow | 119,102,000,000.00 | P/CF | 9.56 |
| Income | Earnings per Share (diluted) | 23.02 | Div. Yield | 4.55 % |
| Income | Net Income | 102,434,000,000.00 | P/E | 11.12 |
| Income | Shares Outstanding | 4,449,000,000.00 | P/B | 5.87 |
| Income | Total Revenue | 309,064,000,000.00 | P/S | 3.68 |
Ratios calculated on: 10/14/2026
Company Description
Novo Nordisk A/S is a Denmark-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company reports two business segments: Diabetes care and Biopharmaceuticals. The Diabetes care division offers a range of diabetes products, including insulin pens and needles, such as FlexPen, NovoPen and FlexTouch, among others, and diabetes medicine, such as insulin- and non-insulin treatment, among others. The Biopharmaceuticals division provides products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas. As of December 31, 2012, the Company marketed its products in five reported geographical regions, namely North America, Europe, Region China, Japan and Korea, as well as International Operations. The Company wholly owns over 70 subsidiaries, such as Novo Nordisk Pharma GmbH, Novo Nordisk Canada Inc., Novo Nordisk Region Japan & Korea A/S, among others.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.novonordisk.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more